1-(5-Cyclopropyl-3-methylpyridin-2-yl)piperazine → (6-Bromo-2-methylpyridin-3-yl)[4-(5-cyclopropyl-3-methylpyridin-2-yl)piperazin-1-yl]methanone
反応式
[Br:1][C:2]1[CH:10]=[CH:9][C:5]([C:6]([OH:8])=O)=[C:4]([CH3:11])[N:3]=1.[CH:12]1([C:15]2[CH:16]=[C:17]([CH3:27])[C:18]([N:21]3[CH2:26][CH2:25][NH:24][CH2:23][CH2:22]3)=[N:19][CH:20]=2)[CH2:14][CH2:13]1>>[Br:1][C:2]1[N:3]=[C:4]([CH3:11])[C:5]([C:6]([N:24]2[CH2:25][CH2:26][N:21]([C:18]3[C:17]([CH3:27])=[CH:16][C:15]([CH:12]4[CH2:13][CH2:14]4)=[CH:20][N:19]=3)[CH2:22][CH2:23]2)=[O:8])=[CH:9][CH:10]=1参加物
3
実験手順
Using 6-bromo-2-methylnicotinic acid (864 mg) and 1-(5-cyclopropyl-3-methylpyridin-2-yl)piperazine (913 mg) described in Preparation Example 83 and by the reaction and treatment in the same manner as in Preparation Example 111, the title compound (948 mg) was obtained.
後処理
- customdescribed in Preparation Example 83 and by the reaction and treatment in the same manner as in Preparation Example 111